Zacks Investment Research downgraded shares of NEOGENOMICS INC (NEO) from OUTPERFORM to NEUTRAL on February 27, 2015, with a target price of $4.90.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
To get a free copy of the research report on NEOGENOMICS INC (NEO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment